Zealand Historical Balance Sheet From 2010 to 2020

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;padding-top: 25px;;'>ZP</div>
ZEAL -- Denmark Stock  

DKK 247.60  18.80  7.06%

Trend analysis of Zealand Pharma AS balance sheet accounts such as Receivables of 6.1 M, Accounts Payable of 31.7 M, Total Assets of 535 M or Current Assets of 517 M provides information on Zealand Pharma total assets, its liabilities, and its equity which is the actual value of Zealand Pharma AS to its prevalent stockholders. By breaking down trends over time using Zealand Pharma balance sheet statements, investors will see what exactly the company owned and what it owed to creditors or other parties at the end of each accounting year. Financial Statement Analysis is much more than just reviewing and breaking down Zealand Pharma AS prevalent accounting reports in order to predict its past. Macroaxis encourages investors to analyze financial statement over time for various trends across multiple indicators and accounts to determine whether Zealand Pharma AS is a good buy for the upcoming year. Check out Your Current Watchlist.

Search Historical Statements

 
Refresh

About Zealand Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Zealand Pharma AS at a specified time, usually calculated after every quarter, six months, or one year. Zealand Pharma Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Zealand Pharma and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Zealand currently owns. An asset can also be divided into two categories, current and non-current.

Zealand Pharma Balance Sheet Chart

Zealand Pharma Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Zealand Pharma AS uses and utilizes its capital. It also shows what exactly a company owns and owes. Zealand Pharma Receivables is quite stable at the moment as compared to the last year. The company current value of Receivables is estimated at about 6.14 Million. Accounts Payable is projected to rize to about 31.7 M this year, although the value of Total Assets will most likely fall to about 535 M.
Add Fundamental
Total Assets    Current Assets    Cash and Equivalents    Shareholders Equity    Total Liabilities    

Total Assets

Total assets refers to the total amount of Zealand Pharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Zealand Pharma AS books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Major components are Cash and Equivalents; [Investments]; [Intangibles]; [PPNENet]; [TaxAssets] and [Receivables].

Current Assets

Current assets of Zealand Pharma AS include cash, cash equivalents, short-term investments, accounts receivable, stock inventory and the portion of prepaid liabilities which will be paid within a year. Depending on the nature of the business, current assets can range from barrels of crude oil, to baked goods, to foreign currency. Current assets are important because they are the assets that are used to fund day-to-day operations of Zealand Pharma. The current portion of Total Assets; reported if a company operates a classified balance sheet that segments current and non-current assets.

Cash and Equivalents

A component of Total Assets representing the amount of currency on hand as well as demand deposits with banks or financial institutions.

Shareholders Equity

A principal component of the balance sheet; in addition to Total Liabilities and Total Assets; that represents the total of all stockholders' equity (deficit) items; net of receivables from officers; directors; owners; and affiliates of the entity which are attributable to the parent.

Total Liabilities

Deferred Income Tax is recorded on Zealand Pharma AS balance sheet and a result of income already earned and recognized for accounting, but not tax, purposes. Also, differences between tax laws and accounting methods can result in a temporary difference in the amount of income tax payable by a company. This difference is recorded on Zealand Pharma books as deferred income tax. Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Principal components are [Debt]; [DeferredRev]; [Payables]; Deposit Liabilities; and Tax Liabilities.
Most indicators from Zealand Pharma fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Zealand Pharma AS current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist.
 2017 2018 2019 2020 (projected)
Weighted Average Shares27.85 M30.69 M27.62 M35.99 M
Revenues139.78 M37.98 M43.67 M42.96 M
Zealand Pharma AS, a biotechnology company, engages in the discovery and development of peptide based medicines in Denmark. The company was founded in 1997 and is headquartered in Copenhagen, Denmark. Zealand Pharma operates under Biotechnology classification in Denmark and is traded on Copenhagen Stock Exchange. It employs 191 people.

Zealand Pharma fundamental ratios Correlations

Zealand Pharma Account Relationship Matchups

Zealand Pharma fundamental ratios Accounts

2014201520162017201820192020 (projected)
Receivables34.95 M167.23 M16.89 M26.61 M6.64 M5.98 M6.14 M
Accounts Payable18.49 M21.68 M19.74 M29.43 M32.65 M29.39 M31.71 M
Total Assets596.76 M634.69 M694.63 M737.24 M1.23 B1.11 B535 M
Current Assets575.44 M615.57 M373.17 M703.19 M1.18 B1.06 B517 M
Cash and Equivalents538.27 M418.8 M323.33 M588.72 M860.63 M774.57 M1.54 B
Shareholders Equity252.83 M252.23 M278.19 M528.47 M1.12 B1 B1.08 B
Total Liabilities343.93 M382.46 M416.43 M208.77 M113.52 M102.16 M128.5 M
Current Liabilities76.76 M69.51 M87.55 M75.78 M113.52 M102.16 M54 M
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page